JAHRESPARTNER
AKTUELLES
Gilead Sciences to acquire Tubulis for up to $5 billion
US biopharmaceutical giant Gilead Sciences is acquiring the biotech start-up Tubulis, significantly expanding its oncology division. The transaction includes an upfront cash payment of $3.15 billion, supplemented by potential milestone payments of up to...
Where Science Meets Capital
A new international platform in Berlin connects investors, start-ups and research to accelerate venture creation in biotechnology and artificial intelligence.
Artificial intelligence is transforming biotechnology, diagnostics and drug discovery. At the same time, Europe...
Conxai erhält Kapital – BayBG und Capricorn Partners im Lead
Conxai Technologies konnte mit seiner agentischen KI-Plattform für die Architektur-, Ingengieur- und Bauindustrie im Rahmen einer Finanzierungsrunde 5 Mio. EUR Kapital einsammeln. Als Leadinvestoren haben sich die BayBG Venture Capital und Capricorn Partners beteiligt,...
‘We’ve built robust capabilities to tackle a wide range of issues efficiently’
At WuXi AppTec’s Couvet site in Switzerland, an integrated CRDMO approach is being designed to accelerate the path from discovery to commercial manufacturing. Dr Jinling Chen explains how combining research, development, and manufacturing helps...
BayBG: Stefan Koller und Andreas Käufl werden Geschäftsführer
Wechsel in der Geschäftsführung der BayBG: Stefan Koller ist zum 1. April 2026 zum neuen Geschäftsführer berufen worden. Er folgt auf Peter Herreiner, der in den Ruhestand geht. Koller wird das Beteiligungsgeschäft und die...
BSM Biotech Holding has launched Biotech venture builder to advance IND-stage biotech assets
BSM Biotech Holding GmbH has officially launched operations, positioning itself as a venture builder focused on translating academic research into first-in-class therapeutic assets.
Headquartered in Grainau, Germany, BSM aims to identify promising molecular targets and...